Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands

OBJECTIVES: Patients with early-stage HR+/HER2- N0 breast cancer may receive adjuvant chemotherapy in combination with surgery. However, chemotherapy does not always lead to improved survival and incurs high healthcare costs and increased adverse events. To support decision-making regarding adjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jongh, Felix E., Efe, Reva, Herrmann, Kirsten H., Spoorendonk, Jelle A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553686/
https://www.ncbi.nlm.nih.gov/pubmed/36250028
http://dx.doi.org/10.1155/2022/5909724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553686/
https://www.ncbi.nlm.nih.gov/pubmed/36250028
http://dx.doi.org/10.1155/2022/5909724

Ejemplares similares